Access to healthcare and prevalence of anxiety and depression in persons with epilepsy during the COVID-19 pandemic: A multicountry online survey.
Adult
Anticonvulsants
/ supply & distribution
Anxiety
/ epidemiology
Betacoronavirus
COVID-19
Coronavirus Infections
/ epidemiology
Delivery of Health Care
Depression
/ epidemiology
Epilepsy
/ drug therapy
Female
Health Services Accessibility
Humans
Logistic Models
Male
Middle Aged
Pandemics
Patient Health Questionnaire
Pneumonia, Viral
/ epidemiology
Prevalence
Risk Factors
SARS-CoV-2
Surveys and Questionnaires
COVID-19
Epilepsy
HADS
Mental health
PHQ-9
Journal
Epilepsy & behavior : E&B
ISSN: 1525-5069
Titre abrégé: Epilepsy Behav
Pays: United States
ID NLM: 100892858
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
08
06
2020
revised:
17
07
2020
accepted:
17
07
2020
pubmed:
14
9
2020
medline:
27
11
2020
entrez:
13
9
2020
Statut:
ppublish
Résumé
The objective of this study was to assess access to healthcare and to estimate the prevalence of depression and anxiety among persons with epilepsy (PWE) during the ongoing coronavirus disease 2019 (COVID-19) pandemic. We conducted a multicountry online survey among PWE. Persons with epilepsy were invited to participate through various social media channels. The Hospital Anxiety and Depression Scale (HADS) and 9-item Patient Health Questionnaire (PHQ-9) scale were used to score anxiety and depression. Logistic regression modeling was used to investigate factors associated with anxiety and depression. Three hundred ninety-nine PWE were included (mean age: 38.22 ± 12.09 years), the majority were female (80.2%) and living in high-income countries (83.2%). Two hundred three PWE reported symptoms of a cold since January 2020. Nine (25%) of the 36 PWE tested for COVID were positive. A total of 72 PWE (19.6%) reported problems to obtain antiseizure medication (ASM), which in 25% of cases was directly COVID-related. Of the 399 PWE, 201 (50.4%) screened positive for anxiety according to the HADS; 159 (39.8%) and 187 (46.9%) PWE screened positive for depression based on the HADS and PHQ-9 scale, respectively. Female gender and financial problems were associated with both depression and anxiety. A planned follow-up consultation with the treating physician was associated with a lower risk of depression, whereas difficulties to access ASM treatment increased the odds of depression. In 65/137 (47.4%) PWE with a planned follow-up visit with the treating physician, this consultation was canceled. Innovative approaches are needed to ensure continuity in access to ASM treatment. Healthcare workers should ensure continued follow-up, either through inperson or telehealth appointments, to timely identify symptoms of anxiety and depression and act accordingly.
Identifiants
pubmed: 32920373
pii: S1525-5050(20)30529-1
doi: 10.1016/j.yebeh.2020.107350
pmc: PMC7481834
pii:
doi:
Substances chimiques
Anticonvulsants
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
107350Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest All authors disclose no conflict of interest related to this study.